0

Pacific Biosciences of California, Inc. (NASDAQ:PACB) – Pacific Biosciences Q3 Revenues Jump 83%, Says Sequel II/IIe Installations At All-Time High


Pacific Biosciences Q3 Revenues Jump 83%, Says Sequel II/IIe Installations At All-Time High

  • Pacific Biosciences of California Inc (NASDAQ: PACB) reported Q3 gross sales of $34.9 million, beating the consensus of $33.23 million and up 83% Y/Y. 
  • The corporate positioned 44 Sequel II or IIe devices within the quarter, bringing the full put in base to 326, in comparison with 168 a yr in the past.
  • Of these complete gross sales, product revenues have been $30.5 million, almost double the $15.7 million from a yr in the past, and repair and different revenues have been $4.4 million, up 32% Y/Y.
  • Product income consisted of $15.9 million in instrument income, greater than double the $7.7 million from a yr in the past, and $14.6 million in consumables income, in comparison with $8.0 million in Q3 2020.
  • The gross margin expanded to 45% from 37% in Q3 2020.
  • PacBio’s R&D bills totaled $27.5 million, up 67%, and SG&A prices have been $31.6 million, greater than double $14.8 million in Q3 2020.
  • PacBio’s adjusted internet loss was $(0.23) per share, in comparison with $(0.14) per share, within the prior-year interval, narrowly lacking the Wall Road estimate of $(0.22).
  • As of September 30, the corporate had $1.08 billion in money and investments.
  • Associated Hyperlink: Pacific Biosciences To Purchase DNA Sequencing Agency For Up To $800M, Publicizes $300M Capital Increase For Deal Funding.
  • Worth Motion: PACB shares closed 0.98% greater at $27.95 on Tuesday.

admin

Leave a Reply

Your email address will not be published. Required fields are marked *